<iframe style="width:100%!important;height:75vh!important;" class="gdriveviewer-iframe" src="https://docs.google.com/gview?embedded=true&url=https://www.sochob.cl/web1/wp-content/uploads/2022/10/Clinical-perspectives-on-the-use-of-the-GIP-GLP-1-receptor-agonist-tirzepatide-for-the-treatment-of-type-2-diabetes-and-obesity.pdf"></iframe><a target="_blank" style="margin-top:2rem;display:block"  href="https://www.sochob.cl/web1/wp-content/uploads/2022/10/Clinical-perspectives-on-the-use-of-the-GIP-GLP-1-receptor-agonist-tirzepatide-for-the-treatment-of-type-2-diabetes-and-obesity.pdf">Descargar Publicación</a>{"id":16852,"date":"2022-10-17T11:07:44","date_gmt":"2022-10-17T15:07:44","guid":{"rendered":"https:\/\/www.sochob.cl\/web1\/?p=16852"},"modified":"2022-10-17T11:07:44","modified_gmt":"2022-10-17T15:07:44","slug":"clinical-perspectives-on-the-use-of-the-gip-glp-1-receptor-agonist-tirzepatide-for-the-treatment-of-type-2-diabetes-and-obesity","status":"publish","type":"post","link":"https:\/\/www.sochob.cl\/web1\/clinical-perspectives-on-the-use-of-the-gip-glp-1-receptor-agonist-tirzepatide-for-the-treatment-of-type-2-diabetes-and-obesity\/","title":{"rendered":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity"},"content":{"rendered":"\n","protected":false},"excerpt":{"rendered":"<p><img decoding=\"async\" width=\"20px;\" style=\"box-shadow:none!important;margin:0 0.5rem;\" src=\"https:\/\/www.sochob.cl\/web1\/wp-content\/plugins\/gdrive-viewer\/includes\/..\/assets\/images\/document.png\">Para ver el documento haz click <a style=\"color:#00A1E7\" data-url=\"https:\/\/www.sochob.cl\/web1\/wp-content\/uploads\/2022\/10\/Clinical-perspectives-on-the-use-of-the-GIP-GLP-1-receptor-agonist-tirzepatide-for-the-treatment-of-type-2-diabetes-and-obesity.pdf\" id=\"gdriver_show_document\" href=\"#\">aqu\u00ed<\/a><\/p>\n<p><p><i style=\"color: #00A1E7;\n    font-size: 20px;\n    margin: 0 0.6rem;\" class=\"fas fa-file-download\"><\/i>Para descargar el documento haz click <a style=\"color:#00A1E7\" href=\"https:\/\/www.sochob.cl\/web1\/wp-content\/uploads\/2022\/10\/Clinical-perspectives-on-the-use-of-the-GIP-GLP-1-receptor-agonist-tirzepatide-for-the-treatment-of-type-2-diabetes-and-obesity.pdf\">aqu\u00ed<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[16],"tags":[],"class_list":["post-16852","post","type-post","status-publish","format-standard","hentry","category-tratamiento-de-la-obesidad"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/posts\/16852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/comments?post=16852"}],"version-history":[{"count":1,"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/posts\/16852\/revisions"}],"predecessor-version":[{"id":16854,"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/posts\/16852\/revisions\/16854"}],"wp:attachment":[{"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/media?parent=16852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/categories?post=16852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sochob.cl\/web1\/wp-json\/wp\/v2\/tags?post=16852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}